Vaginal distribution and retention of tablets comprising starch-based multiparticulates: Evaluation by colposcopy

Drug Development and Industrial Pharmacy

Volumn 39, Issue 12, 2013, Pages 1944-1950

  Mehta, Samata ^a   Verstraelen, Hans ^b   Vandaele, Leen ^a   Mehuys, Els ^a   Remon, Jean Paul ^a   Vervaet, Chris ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Colposcopy; Pellets; Tablets; Vaginal drug delivery

Indexed keywords

STARCH;

ADULT; ANIMAL EXPERIMENT; ARTICLE; COLPOSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; NONHUMAN; NORMAL HUMAN; SHEEP; TABLET; TABLET DISINTEGRATION; TABLET FORMULATION; VAGINA;

ADMINISTRATION, INTRAVAGINAL; ADULT; ANIMALS; COLPOSCOPY; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FEMALE; HUMANS; SHEEP; STARCH; TABLETS; TIME FACTORS; TISSUE DISTRIBUTION; VAGINA; YOUNG ADULT;

EID: 84887261399     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.723217     Document Type: Article

References (26)

1. Hussain A, Ahsan F. (2005). The vagina as a route for systemic drug delivery. J Control Release, 103:301-313. (Pubitemid 40342532)
2. Vermani K, Garg S. (2000). The scope and potential of vaginal drug delivery. Pharm Sci Technol Today, 3:359-364.
3. Justin-Temu M, Damian F, Kinget R, Van Den Mooter G. (2004). Intravaginal gels as drug delivery systems. J Womens Health (Larchmt), 13:834-844. (Pubitemid 39369265)
4. Broumas AG, Basara LA. (2000). Potential patient preference for 3-day treatment of bacterial vaginosis: responses to new suppository form of clindamycin. Adv Ther, 17:159-166. (Pubitemid 30660335)
5. Garg S, Tambwekar KR, Vermani K, Kandarapu R, Garg A, Waller DP et al. (2003). Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges. AIDS Patient Care STDS, 17:377-399. (Pubitemid 37034254)
6. Bernkop-Schnurch A, Hornof M. (2003). Intravaginal Drug Delivery Systems: Design, Challenges, and Solutions. American Journal of Drug Delivery, 1:241-254.
7. Brown J, Hooper G, Kenyon CJ, Haines S, Burt J, Humphries JM et al. (1997). Spreading and retention of vaginal formulations in postmenopausal women as assessed by gamma scintigraphy. Pharm Res, 14:1073-1078. (Pubitemid 27371409)
8. Poelvoorde N, Verstraelen H, Verhelst R, Saerens B, De Backer E, dos Santos Santiago GL et al. (2009). In vivo evaluation of the vaginal distribution and retention of a multi-particulate pellet formulation. Eur J Pharm Biopharm, 73:280-284.
9. Remon JP, Vervaet C, Foreman P. Pharmaceutical Pellets Comprising Modified Starch and Therapeutic Applications Therefor. US Patent App. 20,100/105,784; 2009.
10. Mehta S, Verstraelen H, Peremans K, Villeirs G, Vermeire S, De Vos F et al. (2012). Vaginal distribution and retention of a multiparticulate drug delivery system, assessed by gamma scintigraphy and magnetic resonance imaging. Int J Pharm, 426:44-53.
11. Mehta S, De Beer T, Remon JP, Vervaet C. (2012). Effect of disintegrants on the properties of multiparticulate tablets comprising starch pellets and excipient granules. Int J Pharm, 422:310-317.
12. Mauck CK, Baker JM, Birnkrant DB, Rowe PJ, Gabelnick HL. (2000). The use of colposcopy in assessing vaginal irritation in research. AIDS, 14:2221-2227.
13. Dukic A, Mens R, Adriaensens P, Foreman P, Gelan J, Remon JP et al. (2007). Development of starch-based pellets via extrusion/ spheronisation. Eur J Pharm Biopharm, 66:83-94. (Pubitemid 46412962)
14. Yamaguchi M, Tanno K, Sugibayashi K, Morimoto Y. (1990). Disintegration test to measure lot-to-lot variations of vaginal tablets. Chem Pharm Bull, 38:2314-2316. (Pubitemid 20338213)
15. Owen DH, Katz DF. (1999). A vaginal fluid simulant. Contraception, 59:91-95. (Pubitemid 29244754)
16. Chatterton BE, Penglis S, Kovacs JC, Presnell B, Hunt B. (2004). Retention and distribution of two 99mTc-DTPA labelled vaginal dosage forms. Int J Pharm, 271:137-143. (Pubitemid 38210091)
17. Digenis GA. Gamma-Scintigraphy for estimation of vaginal drug distribution. (1999). 10th World Congress on Human Reproduction. Salvador, Brazil: Elsevier Science Bv.
18. Mauck CK, Katz D, Sandefer EP, Nasution MD, Henderson M, Digenis GA et al. (2008). Vaginal distribution of Replens and K-Y Jelly using three imaging techniques. Contraception, 77:195-204.
19. Barnhart KT, Pretorius ES, Shaunik A, Timbers K, Nasution M, Mauck C. (2005). Vaginal distribution of two volumes of the novel microbicide gel cellulose sulfate (2.5 and 3.5 mL). Contraception, 72:65-70. (Pubitemid 40827121)
20. Barnhart KT, Pretorius ES, Shera DM, Shabbout M, Shaunik A. (2006). The optimal analysis of MRI data to quantify the distribution of a microbicide. Contraception, 73:82-87. (Pubitemid 41811195)
21. Barnhart KT, Pretorius ES, Timbers K, Shera D, Shabbout M, Malamud D. (2004). In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception, 70:498-505. (Pubitemid 39488208)
22. Barnhart KT, Pretorius ES, Timbers K, Shera D, Shabbout M, Malamud D. (2005). Distribution of a 3.5 mL (1.0%) C31G vaginal gel using magnetic resonance imaging. Contraception, 71:357-361. (Pubitemid 40602314)
23. Barnhart KT, Stolpen A, Pretorius ES, Malamud D. (2001). Distribution of a spermicide containing Nonoxynol-9 in the vaginal canal and the upper female reproductive tract. Hum Reprod, 16:1151-1154. (Pubitemid 32544685)
24. Pretorius ES, Timbers K, Malamud D, Barnhart K. (2002). Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse. Contraception, 66:443-451. (Pubitemid 37338061)
25. Schwartz JL, Ballagh SA, Kwok C, Mauck CK, Weiner DH, Rencher WF et al. (2007). Fourteen-day safety and acceptability study of the universal placebo gel. Contraception, 75:136-141. (Pubitemid 46108723)
26. Ballagh SA, Baker JM, Henry DM, Archer DF. (2002). Safety of single daily use for one week of C31G HEC gel in women. Contraception, 66:369-375. (Pubitemid 35346611)